American Regent vs. Long Grove: Selenium Patent Suit Ends in Swift Voluntary Dismissal in Delaware
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | American Regent, Inc. v. Long Grove Pharmaceuticals, LLC |
| Fallnummer | 1:24-cv-00825 (D. Del.) |
| Gericht | US-Bezirksgericht für den Bezirk Delaware |
| Dauer | July 16, 2024 – August 19, 2024 34 days |
| Ergebnis | Freiwillige Klagerücknahme durch den Kläger (ohne Präjudiz) |
| Streitige Patente | |
| Beschuldigte Produkte | Long Grove Selenious Acid Formulations (Eq. 600 mcg, 60 mcg, 12 mcg Selenium) |
Fallübersicht
Die Parteien
⚖️ Kläger
New York-based specialty pharmaceutical company and a subsidiary of Luitpold Pharmaceuticals. American Regent has a well-established portfolio of injectable pharmaceutical products, including micronutrient formulations used in parenteral nutrition.
🛡️ Beklagter
Pharmaceutical company offering competing selenium formulations. Its accused products directly mirror the concentration profiles of American Regent’s products, suggesting Long Grove entered the market with a parallel product line targeting the same clinical applications.
Das streitige Patent
This case involved U.S. Patent No. US11998565B2 (Application No. US18/124391), covering selenious acid formulations for parenteral selenium supplementation. Selenious acid is a critical trace element administered intravenously to patients receiving total parenteral nutrition (TPN). The patent’s claims likely cover specific concentration thresholds, formulation parameters, or manufacturing processes that distinguish the covered products from prior art alternatives.
- • US11998565B2 — Selenious acid formulations for intravenous selenium supplementation.
Entwickeln Sie ein ähnliches pharmazeutisches Produkt?
Check if your formulation might infringe this or related patents before launch.
Das Urteil und die rechtliche Analyse
Ergebnis
The case was terminated by voluntary dismissal without prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i). No damages were awarded. No injunctive relief was granted or denied. No judicial ruling on the merits was issued. Because the dismissal was without prejudice, American Regent retains the right to refile the same claims against Long Grove in a future action, subject to applicable statutes of limitations and any procedural constraints.
Note: Specific settlement terms, licensing agreements, or underlying commercial arrangements, if any, were not disclosed in the public record.
Wichtige rechtliche Fragen
The strategic calculus behind a Rule 41(a)(1)(A)(i) dismissal at this juncture is instructive. This mechanism is only available prior to the defendant’s answer or summary judgment motion — meaning American Regent acted swiftly and deliberately. Possible explanations include:
- Out-of-court resolution: Parties may have reached a licensing agreement or consent arrangement off the docket.
- Patent prosecution development: Activity on Application No. US18/124391 may have warranted reassessment of claim scope before proceeding.
- Tactical repositioning: Plaintiff may have identified a stronger legal theory, additional patents, or preferred venue for a subsequent action.
- Commercial negotiation: A business resolution may have rendered continued litigation unnecessary.
While this case produced no precedential ruling, it highlights the increasing use of voluntary dismissal as a strategic tool in ANDA-adjacent pharmaceutical patent litigation.
Freedom to Operate (FTO) Analysis for Pharmaceutical Formulations
Dieser Fall verdeutlicht die kritischen IP-Risiken bei der Entwicklung spezieller pharmazeutischer Formulierungen. Wählen Sie Ihren nächsten Schritt:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Arzneimittelprozesses.
- View all related patents in the selenious acid technology space
- Sehen Sie, welche Unternehmen im Bereich der Patente für parenterale Ernährung am aktivsten sind
- Muster bei der Auslegung von Ansprüchen für ähnliche Formulierungen verstehen
🔍 Das Risiko meines Produkts überprüfen
Führen Sie eine umfassende FTO-Analyse für Ihre eigene pharmazeutische Technologie oder Ihr Produkt durch.
- Input your product description or technical formulation features
- AI identifies potentially blocking patents in clinical nutrition
- Get actionable risk assessment report for your IP team
Hochrisikogebiet
Identical selenious acid concentration profiles
1 Schlüsselpatent
US11998565B2 at issue
Design-Around-Optionen
Potential for formulation tweaks
✅ Wichtigste Erkenntnisse
Rule 41(a)(1)(A)(i) voluntary dismissal without prejudice is a tactically viable tool when litigation timing requires adjustment post-filing.
Verwandte Rechtsprechung suchen →A complaint filed and voluntarily dismissed without prejudice can serve legitimate strategic purposes, including signaling enforcement intent or initiating licensing discussions.
Erforschen Sie Prozessstrategien →Häufig gestellte Fragen
The case involved U.S. Patent No. US11998565B2 (Application No. US18/124391), covering selenious acid formulations used for intravenous selenium supplementation.
American Regent voluntarily dismissed all claims without prejudice under Fed. R. Civ. P. 41(a)(1)(A)(i) after 34 days. No public explanation was provided; potential reasons include out-of-court resolution, licensing negotiations, or strategic repositioning.
Yes. A without-prejudice dismissal preserves American Regent’s right to refile the same claims against Long Grove, subject to applicable statutes of limitations.
A ‘without prejudice’ dismissal allows the plaintiff to refile the lawsuit later. In pharma patent litigation, this can be a strategic move to re-evaluate claims, pursue licensing, or consolidate litigation efforts, offering flexibility without conceding on the merits.
Sind Sie bereit, Ihre Strategie für pharmazeutische Patente zu stärken?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the pharma sector.
Referenzen
- PACER — Case No. 1:24-cv-00825, D. Del.
- USPTO Patent Center — US11998565B2
- Cornell Legal Information Institute — Fed. R. Civ. P. 41
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.